RTOG-0627

Terminated

Return to Protocol Table

Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme

Principal Investigator

Andrew B. Lassman

Status

Terminated

Closed to Accrual

March 22, 2011

Closed to Accrual & Treatment

May 31, 2018

Complete

May 31, 2018

Terminated

September 4, 2018


Disease Site

Brain [BN] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To determine the therapeutic efficacy of dasatinib in all patients (i.e., stages 1B and 2 combined) with recurrent/progressive GBM as measured by 6-month progression-free survival.

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Patients with GBM who have progressive/recurrent disease despite treatment with radiotherapy and temozolomide. Patients accrued to stage 1 (closed to accrual) or stage 1B (opened to accrual May 5, 2009) require overexpression/activity in at least two of the following SRC, KIT, PDGFR, and EPHA2. Patients accrued to stage 2 (cohort closed; not currently applicable) do not require overexpression/activity.

Target Accrual

84

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.